Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

237
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
237
Pharmacovigilance01:19

Pharmacovigilance

784
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
784
Chronopharmacokinetics: Circadian Rhythms and Influence on Drug Response01:15

Chronopharmacokinetics: Circadian Rhythms and Influence on Drug Response

48
Circadian rhythms are cyclic changes that are crucial in plasma drug concentrations. Various standard circadian parameters, including core body temperature, heart rate, and other cardiovascular factors, directly impact disease states and the therapeutic response to drug therapy.
The time of drug administration is an important factor to consider, as it can influence the toxic dose of a drug. For example, a study conducted by Prins et al. in 1997 examined the effects of the timing of...
48
Preclinical Development: Overview01:28

Preclinical Development: Overview

4.3K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.3K
Clinical Trials: Overview01:11

Clinical Trials: Overview

2.9K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.9K
Pharmacokinetic Models: Comparison and Selection Criterion01:26

Pharmacokinetic Models: Comparison and Selection Criterion

48
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
48

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Microbiome-Modulating Strategies in Anticancer Therapy: A Review of Current Evidence and Recommendations for Further Treatment Improvement.

Probiotics and antimicrobial proteins·2026
Same author

Clinical Validation of Venetoclax Volumetric Microsampling in Patients with Leukemia with Assessment of Whole-Blood-to-Plasma Conversion Strategies and Self-Microsampling Feasibility.

Clinical pharmacokinetics·2026
Same author

Academic-industry collaboration in biomedical innovation: A multi-model review of barriers and facilitators.

Drug discovery today·2025
Same author

Dried blood spot LC-MS/MS quantification of voclosporin in renal transplant recipients using volumetric dried blood spot sampling.

Journal of pharmaceutical and biomedical analysis·2024
Same author

Tamoxifen pharmacokinetics and pharmacodynamics in older patients with non-metastatic breast cancer.

Breast cancer research and treatment·2023
Same author

Genetic variants found in paediatric oncology patients with severe chemotherapy-induced toxicity: A case series.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners·2022

Related Experiment Video

Updated: Jun 11, 2025

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
05:53

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

10.1K

Pharmacogenetic Panel Testing: A Review of Current Practice and Potential for Clinical Implementation.

R Mosch1, M van der Lee1, H J Guchelaar1

  • 1Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands;

Annual Review of Pharmacology and Toxicology
|September 30, 2024
PubMed
Summary

Pharmacogenetics (PGx) panel testing uses genetic profiles to personalize drug selection and dosage. Evidence supports pretherapeutic PGx panel testing for guideline-recommended drugs, but more data is needed for widespread clinical use.

Keywords:
adverse drug reactionsimplementationpanel testingpersonalized medicinepharmacogeneticsprecision medicine

More Related Videos

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
07:40

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis

Published on: March 20, 2021

16.6K
Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation
07:15

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation

Published on: January 16, 2019

10.9K

Related Experiment Videos

Last Updated: Jun 11, 2025

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
05:53

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

10.1K
Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
07:40

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis

Published on: March 20, 2021

16.6K
Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation
07:15

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation

Published on: January 16, 2019

10.9K

Area of Science:

  • Pharmacogenetics and Precision Medicine
  • Clinical Pharmacology
  • Genomic Medicine

Background:

  • Pharmacogenetics (PGx) optimizes drug therapy using individual genetic profiles.
  • Current clinical practice includes reactive and pretherapeutic single-gene PGx tests.
  • Over 95% of individuals possess actionable PGx variants impacting common medications.

Purpose of the Study:

  • To review the current status of PGx panel testing.
  • To explore the potential for clinical implementation of PGx panel testing.
  • To evaluate the evidence supporting preemptive PGx testing.

Main Methods:

  • Review of current literature on PGx panel testing.
  • Analysis of existing clinical guidelines for PGx testing.
  • Discussion of implementation challenges and requirements.

Main Results:

  • Pretherapeutic PGx panel testing is supported by available evidence for guideline-covered drugs.
  • Actionable PGx variants are prevalent in the general population.
  • Drugs affected by PGx variants are widely prescribed.

Conclusions:

  • Evidence supports pretherapeutic PGx panel testing for specific drugs.
  • Further research is needed to identify optimal patient populations.
  • Cost-effectiveness data is crucial for large-scale implementation of PGx panel testing.